ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
114.51
+3.87 (3.50%)
At close: Dec 5, 2025, 4:00 PM EST
117.80
+3.29 (2.87%)
After-hours: Dec 5, 2025, 7:56 PM EST
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 69 employees as of December 31, 2024. The number of employees increased by 8 or 13.11% compared to the previous year.
Employees
69
Change (1Y)
8
Growth (1Y)
13.11%
Revenue / Employee
$102,513
Profits / Employee
-$3,325,555
Market Cap
8.29B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABVX News
- 17 days ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 27 days ago - Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026 - Seeking Alpha
- 7 weeks ago - Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster - Seeking Alpha
- 2 months ago - ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 2 months ago - Why Is Abivax Stock Trading Higher On Monday? - Benzinga
- 2 months ago - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewsWire
- 2 months ago - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 2 months ago - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire